Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cellebrite DI (CLBT) Operating Expenses (2020 - 2025)

Historic Operating Expenses for Cellebrite DI (CLBT) over the last 6 years, with Q3 2025 value amounting to $86.7 million.

  • Cellebrite DI's Operating Expenses rose 2050.33% to $86.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $321.4 million, marking a year-over-year increase of 1943.19%. This contributed to the annual value of $281.7 million for FY2024, which is 1804.46% up from last year.
  • Cellebrite DI's Operating Expenses amounted to $86.7 million in Q3 2025, which was up 2050.33% from $81.2 million recorded in Q2 2025.
  • In the past 5 years, Cellebrite DI's Operating Expenses ranged from a high of $86.7 million in Q3 2025 and a low of $40.7 million during Q1 2021
  • For the 5-year period, Cellebrite DI's Operating Expenses averaged around $61.8 million, with its median value being $58.7 million (2023).
  • Its Operating Expenses has fluctuated over the past 5 years, first soared by 6406.77% in 2021, then plummeted by 69.38% in 2023.
  • Cellebrite DI's Operating Expenses (Quarter) stood at $51.3 million in 2021, then grew by 1.85% to $52.2 million in 2022, then grew by 20.85% to $63.1 million in 2023, then rose by 19.97% to $75.7 million in 2024, then increased by 14.57% to $86.7 million in 2025.
  • Its last three reported values are $86.7 million in Q3 2025, $81.2 million for Q2 2025, and $77.8 million during Q1 2025.